“
“Objective: To evaluate the prognostic impact of early recurrence (within 12 months) after surgery on cancer-specific survival (CSS) of patients with localized clear-cell renal cell carcinoma (ccRCC). Methods: Patients with surgically treated localized ccRCC were studied. Using the Kaplan-Meier method, we calculated CSS; by univariate and multivariate models we analyzed the association of early recurrence with cancer-related mortality. Results: We identified 259 patients with pT1-4/NX/0M0 ccRCC treated between February 1981 and September 2009; of 66 (25.5%)

with disease recurrence, 29 (43.9%) had buy NCT-501 early relapse. Overall, 43 patients (16.6%) died from ccRCC. The 5- and 10-year CSS for those without, late and early recurrence was 98.5 and 96.5%, 53 and 39.8%, and 23 and 23%, respectively (p < 0.0001). In the multivariate Cox model, pT stage (p = 0.01) and early recurrence (p < 0.0001) independently predicted CSS. Conclusions: Recurrent disease after localized ccRCC confers a poor prognosis, especially if detected within 12 months after surgery. Thus, this criterion should be included as an independent risk factor find more for cancer-related mortality. Copyright (C) 2010

S. Karger AG, Basel”
“The magnetofluctuation conductivity, called excess conductivity, originated from the forming of the superconducting droplet near to the mean-field transition temperature, was measured for the optimally doped BaFe1.8Co0.2As2 single crystals with a critical temperature, T-c, of 24.6 K. This measurement of the excess conductivity for magnetic fields up to 9 T was compared with the thermodynamic scaling theory in the critical region, in which not only the Gaussian fluctuation but also fourth order terms of the order buy LY411575 parameter are included. An analysis of the excess conductivity showed that the superconductivity followed

three-dimensional scaling rather than two-dimensional scaling even though the sample had a layered structure. (C) 2010 American Institute of Physics. [doi: 10.1063/1.3478716]“
“Background: Sunitinib is standard first-line therapy for metastatic clear cell renal cancer (MCRC). It is associated with leucopenia; however, its effects on specific immune cell subsets are unclear. Alterations in immune cell subsets may contribute to tumour progression. Methods: Lymphocyte subsets (CD3, 4, 8, 19 and 56) were measured in 43 untreated MCRC patients who received sunitinib. The protocol included a structured treatment interruption of 5 weeks. Cell populations were measured at specific time points during sunitinib treatment and the treatment break. Results: Sunitinib was associated with significant declines in total leucocyte (-48%), neutrophil (-62%), CD3 total T cell (-31%) and CD4 counts (32%; p < 0.05). There was no significant change in CD19 B lymphocyte, CD8 or CD56 natural killer cells. During the sunitinib-free interval, all parameters recovered to baseline.